M6A-dependent regulation of microRNAs from CKD stage 5 patients: insights from epigenetic modification analysis

Area of Science:

• Molecular Biology
• Genomics
• Immunology

Background:

• Chronic kidney disease (CKD) stage 5 is associated with systemic inflammation.
• Peripheral blood mononuclear cells (PBMCs) are crucial in this inflammatory process.
• Epitranscriptomic modifications, like N6-methyladenosine (m6A), are increasingly recognized in disease.

Purpose of the Study:

• To investigate the m6A epitranscriptomic landscape of small RNAs in PBMCs from CKD stage 5 patients.
• To identify specific small RNAs and their modification patterns altered in CKD stage 5.
• To explore potential miRNA-target gene interactions relevant to CKD pathogenesis.

Main Methods:

• Small RNA modification microarrays were used to profile m6A levels in PBMCs.
• Differential m6A-modified small RNAs (miRNAs, pre-miRNAs, tsRNAs) were identified.
• Bioinformatic analyses, including enrichment analysis and target prediction, were performed.
• Quantitative PCR (qPCR) and Mass Spectrometry-based RNA immunoprecipitation (MeRIP) validated key findings.

Main Results:

• 158 miRNAs, 149 pre-miRNAs, and 197 tsRNAs exhibited differential m6A modification.
• Enrichment analysis pointed to pathways like PI3K-Akt signaling and leukocyte transendothelial migration.
• IRF1 and RUNX2 were identified as key target genes.
• Reduced m6A was confirmed in miR-205-3p and miR-93-5p, correlating with RUNX2 upregulation and IRF1 downregulation.

Conclusions:

• CKD stage 5 is characterized by a distinct m6A epitranscriptomic profile in PBMC small RNAs.
• Specific miRNA-target gene axes, such as miR-205-3p/RUNX2 and miR-93-5p/IRF1, are implicated.
• These findings suggest potential utility of these altered small RNA modifications as biomarkers for CKD stage 5.